Overview

Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma

Status:
Unknown status

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

Nanjing Sike Pharmaceutical Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Paclitaxel